CoChat

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinase-like orphan receptor 1 (ROR1) molecules for their therapeutic potential against sarcomas. Here, we report that IGF1R (15/15) and ROR1 (11/15) were highly expressed in sarcoma cell lines including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma. IGF1R and ROR1 CAR T cells derived from eight healthy donors using the Sleeping Beauty (SB) transposon system were cytotoxic against sarcoma cells and produced high levels of IFN-γ, TNF-α and IL-13 in an antigen-specific manner. IGF1R and ROR1 CAR T cells generated from three sarcoma patients released significant amounts of IFN-γ in response to sarcoma stimulation. The adoptive transfer of IGF1R and ROR1 CAR T cells derived from a sarcoma patient significantly reduced tumor growth in pre-established, systemically disseminated and localized osteosarcoma xenograft models in NSG mice. Infusion of IGF1R and ROR1 CAR T cells also prolonged animal survival in a localized sarcoma model using NOD/scid mice. Our data indicate that both IGF1R and ROR1 can be effectively targeted by SB modified CAR T cells and that such CAR T cells may be useful in the treatment of high risk sarcoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0133152

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Cell surface expression of chimeric antigen receptor (CAR) and GFP after transfection and expression of IGF1R and ROR1 in a panel of sarcoma cell lines. (A) Schematic representation of the Sleeping Beauty (SB) transposons encoding IGF1R CAR and GFP (pKT2-CaIG), IGF1R and GFP:Zeocin (pKT2-CaIG:Z), ROR1 CAR and GFP (pKT2-CaRG), and ROR1 CAR and GFP:Zeocin (pKT2-CaRG:Z). The CAR contains the 4-1BB signaling domain (not shown). A Caggs promoter and a “self-cleaving” 2A peptide flanking the CAR sequence were used to regulate co-expression of CARs and GFP or GFP-Zeocin fusion in the SB transposon trans vectors, namely pKT2-CaIG, pKT2-CaRG, pKT2-CaIG:Z, and pKT2-CaRG:Z. (B) Expression of CAR and GFP in T cells derived from a sarcoma patient (Patient 1) after transfection of PBMCs with pKT2-CaIG:Z/pCMV-SB100X or pKT2-CaRG:Z/pCMV-SB100X or no DNA (as mock) and selection with zeocin. Similar data were obtained in T cells from other two patients with sarcomas and two healthy donors (data not shown). (C) Flow cytometric analysis of IGF1R expression in sarcoma cell lines including Ewing sarcoma (EWS), alveolar or embryonal rhabdomyosarcoma (ARMS or ERMS), osteosarcoma (OS), and fibrosarcoma (FS). K562 (erythroleukemia), Daudi (B-cell Burkitt lymphoma), MCF7 (breast cancer) cell lines were used as control. (D) Flow cytometric analysis of ROR1 expression in sarcoma cell lines. RPMI8226 (multiple myeloma) cell line was used as control. Similar data shown in (C) and (D) were obtained in at least three independent assays.
Fig 1 Cell surface expression of chimeric antigen receptor (CAR) and GFP after transfection and expression of IGF1R and ROR1 in a panel of sarcoma cell lines. (A) Schematic representation of the Sleeping Beauty (SB) transposons encoding IGF1R CAR and GFP (pKT2-CaIG), IGF1R and GFP:Zeocin (pKT2-CaIG:Z), ROR1 CAR and GFP (pKT2-CaRG), and ROR1 CAR and GFP:Zeocin (pKT2-CaRG:Z). The CAR contains the 4-1BB signaling domain (not shown). A Caggs promoter and a “self-cleaving” 2A peptide flanking the CAR sequence were used to regulate co-expression of CARs and GFP or GFP-Zeocin fusion in the SB transposon trans vectors, namely pKT2-CaIG, pKT2-CaRG, pKT2-CaIG:Z, and pKT2-CaRG:Z. (B) Expression of CAR and GFP in T cells derived from a sarcoma patient (Patient 1) after transfection of PBMCs with pKT2-CaIG:Z/pCMV-SB100X or pKT2-CaRG:Z/pCMV-SB100X or no DNA (as mock) and selection with zeocin. Similar data were obtained in T cells from other two patients with sarcomas and two healthy donors (data not shown). (C) Flow cytometric analysis of IGF1R expression in sarcoma cell lines including Ewing sarcoma (EWS), alveolar or embryonal rhabdomyosarcoma (ARMS or ERMS), osteosarcoma (OS), and fibrosarcoma (FS). K562 (erythroleukemia), Daudi (B-cell Burkitt lymphoma), MCF7 (breast cancer) cell lines were used as control. (D) Flow cytometric analysis of ROR1 expression in sarcoma cell lines. RPMI8226 (multiple myeloma) cell line was used as control. Similar data shown in (C) and (D) were obtained in at least three independent assays.CC BY · PubMed Central
Fig 2 In vitro anti-sarcoma cytotoxicity of IGF1R and ROR1 CAR T cells. (A) Cytotoxicity against IGF1R+ target cells including sarcoma cell lines by SB modified IGF1R CAR T cells derived from two healthy donors. PBL1-IGZ, PBL1-IG, PBL2-IGZ and PBL2-mock T cells were generated by transfection of PBMCs derived from two healthy donors (PBL1 and PBL2) using pKT2-CaIG:Z or pKT2-CaIG plus pCMV-SB100X plasmids or without DNA. PBL-CD19CAR T cells were used as control. PBL1-IGZ: Rh1 vs K562 and OS17 vs K562, p < 0.001 at all 3 E/T ratios. PBL1-IG: Rh1 vs K562 and OS17 vs K562, p < 0.01. PBL2-IGZ: Rh1 vs K562, p < 0.001, OS17 vs K562, p < 0.01. Killing of Rh1 and OS17 in each CAR T cell group was also significant compared to the corresponding tumor cells in mock T cell group (p < 0.05). (B) Cytotoxicity of IGF1R CAR T cells against a panel of sarcoma cell lines. Comparisons in PBL1-IGZ and PBL2-IGZ were conducted between each sarcoma line and K562, P = 0.0001 at all E/T ratios. (C) Cytotoxicity against sarcoma cells by IGF1R CAR T cells derived from four more healthy donors but not by mock T cells. Comparisons in PBL3-IGZ, PBL4-IGZ, PBL5-IGZ and PBL6-IGZ were conducted between Rh30 vs K562 and SaOS2 vs K562, P = 0.0001 at all E/T ratios.(D) Expression of human IGF1R in R- transfected cell line confirmed by flow cytometry. (E) Specific cytotoxicity against human IGF1R transfected cell line by IGF1R CAR T cells. Comparisons in PBL3-IGZ, PBL4-IGZ, PBL5-IGZ and PBL6-IGZ were conducted between R- and R-/IGF1R, P = 0.0001 at all E/T ratios. (F) Expression of ROR1 in DB and RBV-LCL cell lines. ROR1- K562 and ROR1+ RPMI8226 were used as control (data not shown). (G) Cytotoxicity against ROR1+ target cells including a sarcoma cell line by ROR1 CAR T cells derived from two healthy donors. Comparisons in PBL7-RGZ, PBL7-GZ, PBL8-RGZ and PBL8-GZ were conducted between each target cell and K562 at all E/T ratios. PBL7-RGZ: SaOS2 vs K562, p = 0.0001, 0.0008, 0.0001 (E/T of 60:1, 20:1 and 6:1). PBL7-GZ: SaOS2 vs K562, p = 0.0221, 0.0762, 0.1121. PBL8-RGZ: SaOS2 vs K562, p = 0.0001, 0.0009, 0.0041. PBL8-GZ: SAOS2 vs K562, p = 0.2585, 0.8439, 0.9298. P values for DB vs K562 and EBV-LCL vs K562 were not shown. All cytotoxicity data shown are mean ± S.E. of triplicates.
Fig 2 In vitro anti-sarcoma cytotoxicity of IGF1R and ROR1 CAR T cells. (A) Cytotoxicity against IGF1R+ target cells including sarcoma cell lines by SB modified IGF1R CAR T cells derived from two healthy donors. PBL1-IGZ, PBL1-IG, PBL2-IGZ and PBL2-mock T cells were generated by transfection of PBMCs derived from two healthy donors (PBL1 and PBL2) using pKT2-CaIG:Z or pKT2-CaIG plus pCMV-SB100X plasmids or without DNA. PBL-CD19CAR T cells were used as control. PBL1-IGZ: Rh1 vs K562 and OS17 vs K562, p < 0.001 at all 3 E/T ratios. PBL1-IG: Rh1 vs K562 and OS17 vs K562, p < 0.01. PBL2-IGZ: Rh1 vs K562, p < 0.001, OS17 vs K562, p < 0.01. Killing of Rh1 and OS17 in each CAR T cell group was also significant compared to the corresponding tumor cells in mock T cell group (p < 0.05). (B) Cytotoxicity of IGF1R CAR T cells against a panel of sarcoma cell lines. Comparisons in PBL1-IGZ and PBL2-IGZ were conducted between each sarcoma line and K562, P = 0.0001 at all E/T ratios. (C) Cytotoxicity against sarcoma cells by IGF1R CAR T cells derived from four more healthy donors but not by mock T cells. Comparisons in PBL3-IGZ, PBL4-IGZ, PBL5-IGZ and PBL6-IGZ were conducted between Rh30 vs K562 and SaOS2 vs K562, P = 0.0001 at all E/T ratios.(D) Expression of human IGF1R in R- transfected cell line confirmed by flow cytometry. (E) Specific cytotoxicity against human IGF1R transfected cell line by IGF1R CAR T cells. Comparisons in PBL3-IGZ, PBL4-IGZ, PBL5-IGZ and PBL6-IGZ were conducted between R- and R-/IGF1R, P = 0.0001 at all E/T ratios. (F) Expression of ROR1 in DB and RBV-LCL cell lines. ROR1- K562 and ROR1+ RPMI8226 were used as control (data not shown). (G) Cytotoxicity against ROR1+ target cells including a sarcoma cell line by ROR1 CAR T cells derived from two healthy donors. Comparisons in PBL7-RGZ, PBL7-GZ, PBL8-RGZ and PBL8-GZ were conducted between each target cell and K562 at all E/T ratios. PBL7-RGZ: SaOS2 vs K562, p = 0.0001, 0.0008, 0.0001 (E/T of 60:1, 20:1 and 6:1). PBL7-GZ: SaOS2 vs K562, p = 0.0221, 0.0762, 0.1121. PBL8-RGZ: SaOS2 vs K562, p = 0.0001, 0.0009, 0.0041. PBL8-GZ: SAOS2 vs K562, p = 0.2585, 0.8439, 0.9298. P values for DB vs K562 and EBV-LCL vs K562 were not shown. All cytotoxicity data shown are mean ± S.E. of triplicates.CC BY · PubMed Central
Fig 3 Cytokine profiling of IGF1R and ROR1 CAR T cells in response to sarcoma stimulation. (A) Significant production of IFN-γ, TNF-α, and IL-13 by IGF1R and ROR1 CAR T cells derived from a healthy donor. Data shown are mean ± S.E. of duplicates. One out of two representative data is shown. (B) Antigen-specific production of IFN-γ by IGF1R and ROR1 CAR T cells derived from three sarcoma patients. Data shown are mean ± S.E. of duplicates.
Fig 3 Cytokine profiling of IGF1R and ROR1 CAR T cells in response to sarcoma stimulation. (A) Significant production of IFN-γ, TNF-α, and IL-13 by IGF1R and ROR1 CAR T cells derived from a healthy donor. Data shown are mean ± S.E. of duplicates. One out of two representative data is shown. (B) Antigen-specific production of IFN-γ by IGF1R and ROR1 CAR T cells derived from three sarcoma patients. Data shown are mean ± S.E. of duplicates.CC BY · PubMed Central
Fig 4 In vivo anti-sarcoma activity of IGF1R and ROR1 CAR T cells in a disseminated mouse model. (A) The experimental schedule of tumor cell injection, CAR T cell infusion and BLI monitoring. Prior to testing, all mice displayed normal healthy status. B) Bioluminescent imaging (BLI) of tumor growth in NSG mice (three groups, n = 6–8 each) treated with a sarcoma patient derived T cells expressing IGF1R CAR (IGZ), ROR1 CAR (RGZ) or mock T cells. SaOS2-fflucN cells were transduced with a lentiviral vector expressing humanized firefly luciferase and truncated nerve growth factor receptor (NGFR). Two mice in the mock group died of tumor progression on day 8. Four mice in IGZ group died of unknown causes on day 8, 9, 16 and 24, probably due to cytokine storms. (C) Bioluminescent intensity of the mice treated with the T cells. All p values were shown in the right panel table and were verified independently. (D) Animal survival after T-cell therapy. All p values were determined using Mantel-Haenszel logrank test and shown in the right panel table. The p values were independently confirmed. Note that p > 0.05 between mock vs IGZ was likely due to a small sample size.
Fig 4 In vivo anti-sarcoma activity of IGF1R and ROR1 CAR T cells in a disseminated mouse model. (A) The experimental schedule of tumor cell injection, CAR T cell infusion and BLI monitoring. Prior to testing, all mice displayed normal healthy status. B) Bioluminescent imaging (BLI) of tumor growth in NSG mice (three groups, n = 6–8 each) treated with a sarcoma patient derived T cells expressing IGF1R CAR (IGZ), ROR1 CAR (RGZ) or mock T cells. SaOS2-fflucN cells were transduced with a lentiviral vector expressing humanized firefly luciferase and truncated nerve growth factor receptor (NGFR). Two mice in the mock group died of tumor progression on day 8. Four mice in IGZ group died of unknown causes on day 8, 9, 16 and 24, probably due to cytokine storms. (C) Bioluminescent intensity of the mice treated with the T cells. All p values were shown in the right panel table and were verified independently. (D) Animal survival after T-cell therapy. All p values were determined using Mantel-Haenszel logrank test and shown in the right panel table. The p values were independently confirmed. Note that p > 0.05 between mock vs IGZ was likely due to a small sample size.CC BY · PubMed Central
Fig 5 In vivo anti-sarcoma response by IGF1R and ROR1 CAR T cells in a localized tumor mouse model. (A) The experimental schedule of tumor cell injection, CAR T cell infusion and BLI monitoring. Prior to testing, all mice displayed normal healthy status. (B) Bioluminescent imaging (BLI) of tumor growth in NOD/SCID mice (four groups, n = 12–13 each) treated with a sarcoma patient derived T cells expressing IGF1R CAR (IGZ), ROR1 CAR (RGZ) or mock T cells. One group mice were untreated. Two mice in the untreated group died of tumor progression on day 13 and 20 and the other two mice died of unknown causes on day 12 and 13. Three mice in the mock group died of tumor progression on day 7, 12 and 19 andone died of unknown causes on day 13. Three mice in the IGZ group died of unknown causes on day 10 and two died of unknown courses on day 17 and 18. Two mice in the RZG group died of tumor progression on day 12 and 50 andone died of unknown causes on day 13. (C) Bioluminescent intensity of the mice treated with the T cells. All p values were shown in the right panel table and were verified independently. (D) Animal survival after T-cell therapy. All p values were determined by the Mantel-Haenszel logrank test and are shown in the right panel table.
Fig 5 In vivo anti-sarcoma response by IGF1R and ROR1 CAR T cells in a localized tumor mouse model. (A) The experimental schedule of tumor cell injection, CAR T cell infusion and BLI monitoring. Prior to testing, all mice displayed normal healthy status. (B) Bioluminescent imaging (BLI) of tumor growth in NOD/SCID mice (four groups, n = 12–13 each) treated with a sarcoma patient derived T cells expressing IGF1R CAR (IGZ), ROR1 CAR (RGZ) or mock T cells. One group mice were untreated. Two mice in the untreated group died of tumor progression on day 13 and 20 and the other two mice died of unknown causes on day 12 and 13. Three mice in the mock group died of tumor progression on day 7, 12 and 19 andone died of unknown causes on day 13. Three mice in the IGZ group died of unknown causes on day 10 and two died of unknown courses on day 17 and 18. Two mice in the RZG group died of tumor progression on day 12 and 50 andone died of unknown causes on day 13. (C) Bioluminescent intensity of the mice treated with the T cells. All p values were shown in the right panel table and were verified independently. (D) Animal survival after T-cell therapy. All p values were determined by the Mantel-Haenszel logrank test and are shown in the right panel table.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 110

Metadata

Authors
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., Rader, C., Hamby, C. V., Loeb, D. M., Cairo, M. S., & Zhou, X.
Affiliations
  • New York Medical College (US)
  • University of Minnesota (US)
  • Johns Hopkins University (US)
  • Scripps Research Institute (US)
Corresponding author
Zhou, Xianzheng
Venue
PLOS ONE
Published
2015-07-14
Volume
10
Issue
7
Pages
e0133152
ISSN
1932-6203 (ISSN-L)
OpenAlex
W925209273
Cited by
109
References
54
Citations by year
2026: 5 · 2025: 11 · 2024: 10 · 2023: 16 · 2022: 10 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 3
FWCI
2.91
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (R21AI092220, AI092220)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Keywords
chimeric antigen receptor T cells, IGF-1 receptor, ROR1, sarcoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, fibrosarcoma, Sleeping Beauty transposon, adoptive T cell therapy, tumor xenograft models, cytokine production, high-risk sarcoma
MeSH terms
Animals, Bone Neoplasms, DNA Transposable Elements, Humans, Interferon-gamma, Receptors, Antigen, T-Cell, Sarcoma, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Interferon-alpha, Receptors, Somatomedin, Receptor, IGF Type 1, Interleukin-13, Adoptive Transfer, K562 Cells, Cell Line, Tumor, Mice, Receptor Tyrosine Kinase-like Orphan Receptors, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. https://app.cochat.ai/papers/10.1371/journal.pone.0133152
The paper
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., Rader, C., Hamby, C. V., Loeb, D. M., Cairo, M. S., & Zhou, X. (2015). IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLOS ONE. https://doi.org/10.1371/journal.pone.0133152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.